Von Willebrand disease
ICD-10 D68.0 is a billable code used to indicate a diagnosis of von willebrand disease.
Von Willebrand disease (VWD) is a hereditary bleeding disorder caused by a deficiency or dysfunction of von Willebrand factor (VWF), a protein essential for platelet adhesion and aggregation. This condition leads to increased bleeding tendencies, particularly in mucosal areas, and can manifest as easy bruising, prolonged bleeding from cuts, heavy menstrual periods, and spontaneous bleeding episodes. VWD is classified into three main types: Type 1, characterized by a partial quantitative deficiency of VWF; Type 2, which involves qualitative defects of VWF; and Type 3, a severe form with virtually absent VWF. Diagnosis typically involves laboratory tests assessing VWF levels, factor VIII levels, and platelet function. Management may include desmopressin administration, VWF concentrates, and antifibrinolytic agents. Patients with VWD may also have coexisting conditions such as thrombocytopenia or other coagulation defects, necessitating careful evaluation and management to prevent complications associated with bleeding disorders.
Comprehensive documentation of bleeding history, laboratory test results, and treatment plans.
Patients presenting with unexplained bleeding, family history of bleeding disorders, or abnormal laboratory findings.
Ensure accurate documentation of VWF levels and factor VIII levels to support coding.
Detailed patient history, including bleeding episodes and family history.
Routine evaluations of patients with known bleeding disorders or those presenting with bleeding symptoms.
Referral to hematology for further evaluation may be necessary; document all referrals.
Used to evaluate bleeding disorders including VWD.
Document the indication for the CBC and any relevant clinical findings.
Hematology specialists may require additional tests to confirm diagnosis.
Von Willebrand disease is primarily caused by genetic mutations that affect the production or function of von Willebrand factor, leading to impaired platelet adhesion and increased bleeding risk.
